446290-68-2Relevant academic research and scientific papers
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4- fluoro-7-[1,2,3]triazol-1-yl-1H-
Regueiro-Ren, Alicia,Xue, Qiufen M.,Swidorski, Jacob J.,Gong, Yi-Fei,Mathew, Marina,Parker, Dawn D.,Yang, Zheng,Eggers, Betsy,D'Arienzo, Celia,Sun, Yongnian,Malinowski, Jacek,Gao, Qi,Wu, Dedong,Langley, David R.,Colonno, Richard J.,Chien, Caly,Grasela, Dennis M.,Zheng, Ming,Lin, Pin-Fang,Meanwell, Nicholas A.,Kadow, John F.
, p. 1656 - 1669 (2013/04/23)
A series of highly potent HIV-1 attachment inhibitors with 4-fluoro-6-azaindole core heterocycles that target the viral envelope protein gp120 has been prepared. Substitution in the 7-position of the azaindole core with amides (12a,b), C-linked heterocycl
Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
-
Page 169, (2008/06/13)
This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
